Hypertriglyceridemia Therapeutics Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	230 Pages	Coherent Market Insights	July, 2023	CMI18107933

Best Price Guarantee
Price	from $4,500
Length	230 Pages
Publisher	Coherent Market Insights
Published Date	July, 2023
SKU	CMI18107933

Hypertriglyceridemia Therapeutics Market, By Type (Primary and Secondary), By Drug Class (Statins, Fibrates, Omega-3 Fatty Acids, HMG-CoA Reductase inhibitors, and Niacin), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Hypertriglyceridemia is a common disorder in which the triglyceride levels in the body increase. It is often caused or exacerbated by uncontrolled diabetes mellitus, obesity, and sedentary habits, all of which are more prevalent in industrialized societies than in developing nations. This rising levels of triglyceride are majorly associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. Hypertriglyceridemia also causes pancreatitis, atherosclerosis, and other cardiovascular diseases. Currently, the advancements in treatment of hypertriglyceridemia are helping in recovering the triglyceride levels in the human body. Severe hypertriglyceridemia means your triglycerides are 500 mg/dL or higher. People with severe hypertriglyceridemia face an increased risk of acute pancreatitis. This is a pancreatic inflammation that needs medical attention. Most people with hypertriglyceridemia have no symptoms. People with severe hyperglyceridemia may develop xanthomas. These are skin bumps that form when lipids build up under your skin. The xanthomas usually appear around your eyelids. But they may also appear on your knees, elbows or palms of your hands. Genetics- increased triglyceride levels in the blood may be associated with certain genetic diseases or disorders, such as familial combined hyperlipidemia.

Market Dynamics

The ongoing research & development of developing novel drugs is expected to propel the global hypertriglyceridemia market growth during the forecast period. Further, growing prevalence of cardiovascular diseases such as atherosclerosis, hypertension, and coronary heart disease and sedentary lifestyle is also expected to boost the global hypertriglyceridemia therapeutics market over the forecast period. For instance, in February 2020, Esperion Therapeutics, Inc., a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies, announced that the U.S. Food and Drug Administration (FDA) approved NEXLETOL (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.

Key features of the study:

This report provides in-depth analysis of the global hypertriglyceridemia therapeutics market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hypertriglyceridemia therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Sanofi, GSK, plc., Biocon, Novo Nordisk A/S, Tonghua Dongbao Pharmaceutical Co., Ltd., Oramed, AbbVie Inc., Merck & Co., Inc. WOCKHARDT, Pfizer Inc., Julphar, Eli Lilly and Company, Bristol-Myers Squibb Company, ADOCIA, Hikma Pharmaceuticals PLC, Lupin, Zydus Pharmaceuticals, Inc., Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC., Aurobindo Pharma, and Accord Healthcare.
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hypertriglyceridemia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertriglyceridemia therapeutics market

Detailed Segmentation:

Global Hypertriglyceridemia Therapeutics Market, By Type:
Primary
Secondary
Global Hypertriglyceridemia Therapeutics Market By Drug Class:
Statins
Fibrates
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
Niacin
Global Hypertriglyceridemia Therapeutics Market By Distribution Channel:
Retail Pharmacy
Hospitals Pharmacy
Online Pharmacy
Others
Global Hypertriglyceridemia Therapeutics Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Sanofi
GSK, plc.
Biocon
Novo Nordisk A/S
Tonghua Dongbao Pharmaceutical Co., Ltd.
Oramed
AbbVie Inc.
Merck & Co., Inc.
WOCKHARDT
Pfizer Inc.
Julphar
Eli Lilly and Company
Bristol-Myers Squibb Company
ADOCIA
Hikma Pharmaceuticals PLC
Lupin
Zydus Pharmaceuticals, Inc.
Glenmark Pharmaceuticals Ltd.
Amneal Pharmaceuticals LLC.
Aurobindo Pharma
Accord Healthcare

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Type; Market Snapshot, By Drug Class; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Market Attractiveness Analysis; Merger, Acquisition, Collaborations; Funding and Investment; Regulatory Guidelines and Compliances; Key Developments; Pipeline Analysis; PEST Analysis; PORTER’s Analysis
4. Global Hypertriglyceridemia Therapeutics Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Hypertriglyceridemia Therapeutics Market, By Type, 2018-2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018-2030; Segment Trends; Primary; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Secondary; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
6. Global Hypertriglyceridemia Therapeutics Market, By Drug Class, 2018-2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018-2030; Segments Trends; Statins; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Fibrates; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Omega-3 Fatty Acids; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); HMG-CoA Reductase inhibitors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Niacin; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
7. Global Hypertriglyceridemia Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Billion): Introduction; Market Share Analysis, 2023 and 2030 (%); Y-o-Y Growth Analysis, 2018-2030; Segments Trends; Retail Pharmacy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Hospitals Pharmacy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Online Pharmacy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Billion)
8. Global Hypertriglyceridemia Therapeutics Market, By Region, 2018-2030, (US$ Billion): Introduction; Market Share Analysis, By Region, 2023 and 2030 (%); Y-o-Y Growth Analysis, For Region, 2018–2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Billion); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Billion); Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Billion); North Africa; Central Africa; South Africa
9. Competitive Landscape: Sanofi; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; GSK, plc.; Biocon; Novo Nordisk A/S; Tonghua Dongbao Pharmaceutical Co., Ltd.; Oramed; AbbVie Inc.; Merck & Co., Inc.; WOCKHARDT; Pfizer Inc.; Julphar; Eli Lilly and Company; Bristol-Myers Squibb Company; ADOCIA; Hikma Pharmaceuticals PLC; Lupin; Zydus Pharmaceuticals, Inc.; Glenmark Pharmaceuticals Ltd.; Amneal Pharmaceuticals LLC.; Aurobindo Pharma; Accord Healthcare
10. Section: Research Methodology; About Us; *Browse 32 market data tables and 26 figures on “Global Hypertriglyceridemia Therapeutics Market”- Global forecast to 2030